JNJ | Weekly | Haru Insights

Johnson & Johnson received FDA De Novo clearance for its Ottava surgical robotics system, marking a pivotal regulatory milestone and signaling a strategic pivot into integrated surgical robotics within its Ethicon platform.
The company reported a $5.5 billion pretax charge related to talc litigation, driving a 7.5% decline in adjusted EPS for Q3 2026 despite beating revenue and earnings estimates—underscoring ongoing legal risk as a core headwind.

JNJ’s pulsed field ablation pipeline is setting a new gold standard in electrophysiology, with 100% acute success and 82.5% freedom from recurrence at 12 months—positioning it to capture a dominant share of next-gen cardiac rhythm management.
The FDA De Novo approval for Ottava validates JNJ’s surgical robotics ambitions, demonstrating its ability to innovate in high-barrier markets and integrate robotics into a proven surgical ecosystem.
Explosive growth in neuroscience and immunology, driven by Caplyta, Spravato, TREMFYA, and ICOTYDE, reflects strong clinical and commercial momentum in high-value therapeutic areas with durable demand.
JNJ’s ability to deliver top-line beat despite a massive litigation charge signals resilience in its core pharmaceutical engine, reinforcing confidence in its R&D and commercial execution.
The Ottava system’s clearance is more than a product launch—it’s a strategic bet on the future of minimally invasive surgery, potentially unlocking recurring revenue and deepening clinician loyalty across the Ethicon network.

Johnson & Johnson (JNJ)[Tv]